Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.55 |
| ▸ | HTR1A | P08908 | 8/20 | 0.55 |
| ▸ | HTR6 | P50406 | 5/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232333 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| Hydrochloric Acid SCHEMBL2801750 | 0.98 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL29904548 | 0.89 | CHRNB2 (0.51) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL20438926 | 0.89 | CHRNB2 (0.51) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL1822160 | 0.89 | CHRNB2 (0.51) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| Hydrochloric Acid SCHEMBL29051178 | 0.87 | CHRNB2 (0.50) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL434354 | 0.86 | OPRL1 (0.57) | OPRL1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4974123 | 0.85 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HTR1AOPRL1 | |
| SCHEMBL1765151 | 0.85 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| Hydrochloric Acid SCHEMBL6075890 | 0.83 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963268-B1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-01 | — | — | EP | claimed |
| US-20080269286-A1 | Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-10-30 | — | — | US | claimed |
| EP-1963268-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | Neurosearch Sweden AB (SE) | 2008-09-03 | — | — | EP | claimed |
| WO-2007065655-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NEUROSEARCH SWEDEN AB (SE) | 2007-06-14 | — | — | WO | claimed |
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| WO-2023250083-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2007065655-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NEUROSEARCH SWEDEN AB (SE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| EP-1751108-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005108368-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SLC6A2 4436/4885SLC6A4 4489/4885SLC6A3 4268/4885 |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | GRM2, GRM1, GRIN2B | SLC6A2 143/4885SLC6A4 115/4885SLC6A3 122/4885 |
| US-20080269286-A1 | Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission | SLC6A2, SLC18A2, PNMT | SLC6A2 1/4885SLC6A4 15/4885SLC6A3 4/4885 |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | SLC6A2 2232/4885SLC6A4 2945/4885SLC6A3 3242/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | SLC6A2 641/4885SLC6A4 743/4885SLC6A3 1025/4885 |
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | SLC6A2 4291/4885SLC6A4 3665/4885SLC6A3 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.